Skip to main content
SpringerLink
Log in

Successful Vaccines

  • Chapter
  • First Online:
Vaccination Strategies Against Highly Variable Pathogens

Part of the book series: Current Topics in Microbiology and Immunology ((CT MICROBIOLOGY,volume 428))

Abstract

Vaccines are considered one of the most important advances in modern medicine and have greatly improved our quality of life by reducing or eliminating many serious infectious diseases. Successful vaccines have been developed against many of the most common human pathogens, and this success has not been dependent upon any one specific class of vaccine since subunit vaccines, non-replicating whole-virus or whole-bacteria vaccines, and attenuated live vaccines have all been effective for particular vaccine targets. After completing the initial immunization series, one common aspect of successful vaccines is that they induce long-term protective immunity. In contrast, several partially successful vaccines appear to induce protection that is relatively short-lived and it is likely that long-term protective immunity will be critical for making effective vaccines against our most challenging diseases such as AIDS and malaria.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Acosta AM et al (2015) Tdap vaccine effectiveness in adolescents during the 2012 Washington State pertussis epidemic. Pediatrics 135:981–989. https://doi.org/10.1542/peds.2014-3358

  • Acosta PL, Caballero MT, Polack FP (2016) Brief history and characterization of enhanced respiratory syncytial virus disease. Clin Vaccine Immunol 23:189–195. https://doi.org/10.1128/CVI.00609-15

    Article  CAS  PubMed Central  Google Scholar 

  • Adams D et al (2015) Summary of notifiable infectious diseases and conditions—United States, 2013 MMWR Morb Mortal Wkly Rep 62:1–122. https://doi.org/10.15585/mmwr.mm6253a1

  • Advisory Committee on Immunization Practices (1997) Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. MMWR Recomm Rep 46:1–32

    Google Scholar 

  • Advisory Committee on Immunization Practices (2000) Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 49:1–22

    Google Scholar 

  • Alexander HE, Heidelberger M, Leidy G (1944) The protective or curative element in type B H. influenzae rabbit serum. Yale J Biol Med 16:425–434

    CAS  PubMed  PubMed Central  Google Scholar 

  • Alexander LN et al (2004) Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA 292:1696–1701

    CAS  PubMed  Google Scholar 

  • Allen A (2013) Public health. The pertussis paradox. Science 341:454–455. https://doi.org/10.1126/science.341.6145.454

    Article  CAS  PubMed  Google Scholar 

  • Amanna IJ, Carlson NE, Slifka MK (2007) Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 357:1903–1915

    CAS  PubMed  Google Scholar 

  • Amanna IJ, Messaoudi I, Slifka MK (2008) Protective immunity following vaccination: how is it defined? Hum Vaccine 4:316–319 (5751 [pii])

    Google Scholar 

  • Amanna IJ, Slifka MK (2010) Mechanisms that determine plasma cell lifespan and the duration of humoral immunity. Immunol Rev 236:125–138. https://doi.org/10.1111/j.1600-065X.2010.00912.x (IMR912 [pii])

  • Anderson P (1984) The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 149:1034–1035

    CAS  PubMed  Google Scholar 

  • Anderson P, Johnston RB Jr, Smith DH (1972) Human serum activities against Hemophilus influenzae, type b. J Clin Invest 51:31–38. https://doi.org/10.1172/JCI106793

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Arredondo-Garcia JL et al (2018) Four-year safety follow-up of the tetravalent dengue vaccine efficacy randomised controlled trials in Asia and Latin America. Clin Microbiol Infect. https://doi.org/10.1016/j.cmi.2018.01.018

    Article  PubMed  Google Scholar 

  • August A et al (2017) A phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age. Vaccine 35:3749–3759. https://doi.org/10.1016/j.vaccine.2017.05.045

  • Bacungan VJ, de Guzman C, Hermonio E (2018) TIMELINE: The Dengvaxia controversy. CNN Philippines. http://cnnphilippines.com/news/2017/12/09/The-Dengvaxia-controversy.html. Accessed 12 Feb 2018

  • Beck KH, Janney FR (1947) Alexander’s rabbit serum in the treatment of influenzal meningitis; an evaluation of its use in conjunction with sulfonamide compounds. JAMA 73:317–325

    CAS  Google Scholar 

  • Beem M, Wright FH, Hamre D, Egerer R, Oehme M (1960) Association of the chimpanzee coryza agent with acute respiratory disease in children. N Engl J Med 263:523–530. https://doi.org/10.1056/NEJM196009152631101

    Article  CAS  PubMed  Google Scholar 

  • Berkovic SF et al (2006) De-novo mutations of the sodium channel gene SCN1A in alleged vaccine encephalopathy: a retrospective study. Lancet Neurol 5:488–492. https://doi.org/10.1016/S1474-4422(06)70446-X

    Article  CAS  PubMed  Google Scholar 

  • Bhatt S et al (2013) The global distribution and burden of dengue. Nature 496:504–507. https://doi.org/10.1038/nature12060

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bjorkholm B, Bottiger M, Christenson B, Hagberg L (1986) Antitoxin antibody levels and the outcome of illness during an outbreak of diphtheria among alcoholics. Scand J Infect Dis 18:235–239

    CAS  PubMed  Google Scholar 

  • Black S, Friedland LR, Schuind A, Howe B (2006) Immunogenicity and safety of a combined DTaP-IPV vaccine compared with separate DTaP and IPV vaccines when administered as pre-school booster doses with a second dose of MMR vaccine to healthy children aged 4–6 years. Vaccine 24:6163–6171 https://doi.org/10.1016/j.vaccine.2006.04.001

  • Bonsignori M et al (2009) HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infection. J Immunol 183:2708–2717. https://doi.org/10.4049/jimmunol.0901068

    Article  CAS  PubMed  Google Scholar 

  • Borrow R et al (2010) Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine. Clin Vaccine Immunol 17:154–159. https://doi.org/10.1128/CVI.00384-09

    Article  CAS  PubMed  Google Scholar 

  • Brady OJ et al (2012) Refining the global spatial limits of dengue virus transmission by evidence-based consensus. PLoS Negl Trop Dis 6:e1760. https://doi.org/10.1371/journal.pntd.0001760

    Article  PubMed  PubMed Central  Google Scholar 

  • Briere EC, Rubin L, Moro PL, Cohn A, Clark T, Messonnier N (2014) Prevention and control of haemophilus influenzae type b disease: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 63:1–14

    PubMed  Google Scholar 

  • Burke DS, Nisalak A, Johnson DE, Scott RM (1988) A prospective study of dengue infections in Bangkok. Am J Trop Med Hyg 38:172–180

    CAS  PubMed  Google Scholar 

  • Burton DR, Mascola JR (2015) Antibody responses to envelope glycoproteins in HIV-1 infection. Nat Immunol 16:571–576. https://doi.org/10.1038/ni.3158ni.3158 [pii]

  • Capeding MR et al (2014) Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 384:1358–1365. https://doi.org/10.1016/S0140-6736(14)61060-6

    Article  CAS  PubMed  Google Scholar 

  • Cardemil CV et al (2017) Effectiveness of a third dose of MMR vaccine for mumps outbreak control. N Engl J Med 377:947–956. https://doi.org/10.1056/NEJMoa1703309

    Article  PubMed  PubMed Central  Google Scholar 

  • Carter CH et al (1962) Serologic response of children to in-activated measles vaccine. JAMA 179:848–853

    CAS  PubMed  Google Scholar 

  • Centers for Disease Control and Prevention (1996) Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 45:1–30

    Google Scholar 

  • Centers for Disease Control and Prevention (2015a) Cervical cancer statistics. Centers for disease control and prevention. http://www.cdc.gov/cancer/cervical/statistics/. Accessed 18 Apr 2016

  • Centers for Disease Control and Prevention (2015b) Diphtheria. In: Hamborsky J, Kroger A, Wolfe S (eds) Epidemiology and prevention of vaccine-preventable diseases, 13th edn. Public Health Foundation, Washington, D.C., pp 107–118

    Google Scholar 

  • Centers for Disease Control and Prevention (2015c) Hepatitis A. In: Hamborsky J, Kroger A, Wolfe S (eds) Epidemiology and prevention of vaccine-preventable diseases, 13th edn. Public Health Foundation, Washington, D.C., pp 135–148

    Google Scholar 

  • Centers for Disease Control and Prevention (2015d) Human papillomavirus. In: Hamborsky J, Kroger A, Wolfe S (eds) Epidemiology and prevention of vaccine-preventable diseases, 13th edn. Public Health Foundation, Washington, D.C., pp 175–186

    Google Scholar 

  • Centers for Disease Control and Prevention (2015e) Measles. In: Hamborsky J, Kroger A, Wolfe S (eds) Epidemiology and prevention of vaccine-preventable diseases, 13th edn. Public Health Foundation, Washington, D.C., pp 209–230

    Google Scholar 

  • Centers for Disease Control and Prevention (2015f) Tetanus. In: Hamborsky J, Kroger A, Wolfe S (eds) Epidemiology and prevention of vaccine-preventable diseases, 13th edn. Public Health Foundation, Washington, D.C., pp 341–352

    Google Scholar 

  • Chanock RM, Kim HW, Vargosko AJ, Deleva A, Johnson KM, Cumming C, Parrott RH (1961) Respiratory syncytial virus. I. Virus recovery and other observations during 1960 outbreak of bronchiolitis, pneumonia, and minor respiratory diseases in children. JAMA 176:647–653

    CAS  PubMed  Google Scholar 

  • Cherry JD (1999) Pertussis in the preantibiotic and prevaccine era, with emphasis on adult pertussis. Clin Infect Dis 28(Suppl 2):S107–S111. https://doi.org/10.1086/515057

  • Cherry JD, Gornbein J, Heininger U, Stehr K (1998) A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 16:1901–1906

    CAS  PubMed  Google Scholar 

  • Chin J, Magoffin RL, Shearer LA, Schieble JH, Lennette EH (1969) Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol 89:449–463

    CAS  PubMed  Google Scholar 

  • Chlibek R et al (2016) Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults. Vaccine 34:863–868. https://doi.org/10.1016/j.vaccine.2015.09.073s0264-410x(15)01349-3 [pii]

  • Cody CL, Baraff LJ, Cherry JD, Marcy SM, Manclark CR (1981) Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. Pediatrics 68:650–660

    CAS  PubMed  Google Scholar 

  • Day PM, Kines RC, Thompson CD, Jagu S, Roden RB, Lowy DR, Schiller JT (2010) In vivo mechanisms of vaccine-induced protection against HPV infection. Cell Host Microbe 8:260–270. https://doi.org/10.1016/j.chom.2010.08.003

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • de Taeye SW, Moore JP, Sanders RW (2016) HIV-1 Envelope trimer design and immunization strategies to induce broadly neutralizing antibodies. Trends Immunol 37:221–232. https://doi.org/10.1016/j.it.2016.01.007s1471-4906(16)00008-9 [pii]

  • Dooling KL, Guo A, Patel M, Lee GM, Moore K, Belongia EA, Harpaz R (2018) Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines. MMWR Morb Mortal Wkly Rep 67:103–108. https://doi.org/10.15585/mmwr.mm6703a5

    Article  PubMed  PubMed Central  Google Scholar 

  • Einstein MH et al (2014) Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18–45 years: follow-up through month 48 in a phase III randomized study. Hum Vaccin Immunother 10:3455–3465. https://doi.org/10.4161/hv.36117

  • Embree J, Law B, Voloshen T, Tomovici A (2015) Immunogenicity, safety, and antibody persistence at 3, 5, and 10 years postvaccination in adolescents randomized to booster immunization with a combined tetanus, diphtheria, 5-component acellular pertussis, and inactivated poliomyelitis vaccine administered with a hepatitis B virus vaccine concurrently or 1 month apart. Clin Vaccine Immunol 22:282–290. https://doi.org/10.1128/CVI.00682-14

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Epstein JE et al (2011) Live attenuated malaria vaccine designed to protect through hepatic CD8(+) T cell immunity. Science 334:475–480. https://doi.org/10.1126/science.1211548science.1211548 [pii]

  • Faulkner A, Skoff T, Martin S, Cassiday P, Tondella ML, Liang J (2015) Chapter 10: Pertussis. In: Manual for the surveillance of vaccine-preventable diseases. Centers for Disease Control and Prevention, Atlanta, GA

    Google Scholar 

  • Feltes TF et al (2003) Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 143:532–540

    CAS  PubMed  Google Scholar 

  • Fulginiti VA, Eller JJ, Downie AW, Kempe CH (1967) Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated measles virus vaccines. JAMA 202:1075–1080

    CAS  PubMed  Google Scholar 

  • Fulginiti VA, Eller JJ, Sieber OF, Joyner JW, Minamitani M, Meiklejohn G (1969) Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol 89:435–448

    CAS  PubMed  Google Scholar 

  • Furuya-Kanamori L et al (2016) Co-distribution and co-infection of chikungunya and dengue viruses. BMC Infect Dis 16:84. https://doi.org/10.1186/s12879-016-1417-2

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Garon J, Patel M (2017) The polio endgame: rationale behind the change in immunisation. Arch Dis Child 102:362–365. https://doi.org/10.1136/archdischild-2016-311171

    Article  PubMed  Google Scholar 

  • Gellis SS, Stokes J Jr, Brother GM, Hall WM, Gilmore HR, Beyer E, Morrissey RA (1945) The use of human immune serum globulin (gamma globulin) in infectious (epidemic) hepatitis in the Mediterranean theater of operations I. Studies on prophylaxis in two epidemics of infectious hepatitis. JAMA 128:1062–1063

    Google Scholar 

  • Giannini SL et al (2006) Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 24:5937–5949. https://doi.org/10.1016/j.vaccine.2006.06.005 (S0264-410X(06)00709-2 [pii])

  • Glenn GM et al (2016) A randomized, blinded, controlled, dose-ranging study of a respiratory syncytial virus recombinant fusion (F) nanoparticle vaccine in healthy women of childbearing age. J Infect Dis 213:411–422. https://doi.org/10.1093/infdis/jiv406

    Article  CAS  PubMed  Google Scholar 

  • Goulon M, Girard O, Grosbuis S, Desormeau JP, Capponi MF (1972) Antitetanus antibodies. Assay before anatoxinotherapy in 64 tetanus patients. Nouv Presse Med 1:3049–3050

    CAS  PubMed  Google Scholar 

  • Gray GE, Laher F, Lazarus E, Ensoli B, Corey L (2016) Approaches to preventative and therapeutic HIV vaccines. Curr Opin Virol 17:104–109. https://doi.org/10.1016/j.coviro.2016.02.010 (S1879-6257(16)30014-1 [pii])

  • Grohskopf LA, Sokolow LZ, Broder KR, Walter EB, Bresee JS, Fry AM, Jernigan DB (2017) Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices—United States, 2017–18 Influenza Season. MMWR Recomm Rep 66:1–20. https://doi.org/10.15585/mmwr.rr6602a1

    Article  PubMed  PubMed Central  Google Scholar 

  • Guinee VF et al (1966) Cooperative measles vaccine field trial. I. Clinical efficacy. Pediatrics 37:649–665

    CAS  PubMed  Google Scholar 

  • Guzman MG, Kouri G, Bravo J, Valdes L, Vazquez S, Halstead SB (2002) Effect of age on outcome of secondary dengue 2 infections. Int J Infect Dis 6:118–124

    PubMed  Google Scholar 

  • Guzman MG et al (1987) Clinical and serologic study of Cuban children with dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS). Bull Pan Am Health Organ 21:270–279

    CAS  PubMed  Google Scholar 

  • Guzman MG et al (2000) Epidemiologic studies on dengue in Santiago de Cuba, 1997. Am J Epidemiol 152:793–799 (discussion 804)

    Google Scholar 

  • Hadinegoro SR et al (2015) Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med 373:1195–1206. https://doi.org/10.1056/NEJMoa1506223

    Article  CAS  PubMed  Google Scholar 

  • Hall CB et al (2009) The burden of respiratory syncytial virus infection in young children. N Engl J Med 360:588–598. https://doi.org/10.1056/NEJMoa0804877

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Halstead SB, Nimmannitya S, Cohen SN (1970) Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. Yale J Biol Med 42:311–328

    CAS  PubMed  PubMed Central  Google Scholar 

  • Halstead SB, Russell PK (2016) Protective and immunological behavior of chimeric yellow fever dengue vaccine. Vaccine 34:1643–1647. https://doi.org/10.1016/j.vaccine.2016.02.004

    Article  CAS  PubMed  Google Scholar 

  • Hammarlund E et al (2016) Durability of vaccine-induced immunity against tetanus and diphtheria toxins: a cross-sectional analysis. Clin Infect Dis 62:1111–1118. https://doi.org/10.1093/cid/ciw066

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hao L, Toyokawa S, Kobayashi Y (2008) Poisson-model analysis of the risk of vaccine-associated paralytic poliomyelitis in Japan between 1971 and 2000. Jpn J Infect Dis 61:100–103

    PubMed  Google Scholar 

  • Harpaz R, Ortega-Sanchez IR, Seward JF (2008) Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 57:1–30 (quiz CE32-34 doi:rr5705a1 [pii])

    Google Scholar 

  • Havens WP Jr, Paul JR (1945) Prevention of infectious hepatitis with gamma globulin. JAMA 129:270–272

    Google Scholar 

  • Heath PT (1998) Haemophilus influenzae type b conjugate vaccines: a review of efficacy data. Pediatr Infect Dis J 17:S117–S122

    CAS  PubMed  Google Scholar 

  • Heinz FX, Stiasny K, Holzmann H, Grgic-Vitek M, Kriz B, Essl A, Kundi M (2013) Vaccination and tick-borne encephalitis, central Europe. Emerg Infect Dis 19:69–76. https://doi.org/10.3201/eid1901.120458

    Article  PubMed  PubMed Central  Google Scholar 

  • Hoffman SL, Vekemans J, Richie TL, Duffy PE (2015) The march toward malaria vaccines. Vaccine 33(Suppl 4):D13–D23 https://doi.org/10.1016/j.vaccine.2015.07.091s0264-410x(15)01070-1 [pii]

  • Hsia DY, Lonsway M Jr, Gellis SS (1954) Gamma globulin in the prevention of infectious hepatitis; studies on the use of small doses in family outbreaks. N Engl J Med 250:417–419. https://doi.org/10.1056/NEJM195403112501004

    Article  CAS  PubMed  Google Scholar 

  • Innis BL et al (1994) Protection against hepatitis A by an inactivated vaccine. JAMA 271:1328–1334

    CAS  PubMed  Google Scholar 

  • Izurieta HS, Strebel PM, Blake PA (1997) Postlicensure effectiveness of varicella vaccine during an outbreak in a child care center. JAMA 278:1495–1499

    CAS  PubMed  Google Scholar 

  • Jaberolansar N, Toth I, Young PR, Skwarczynski M (2016) Recent advances in the development of subunit-based RSV vaccines. Expert Rev Vaccines 15:53–68. https://doi.org/10.1586/14760584.2016.1105134

    Article  CAS  PubMed  Google Scholar 

  • Jenner E (1798) An inquiry into the causes and effects of the variolae vaccinae. Sampson Low, London

    Google Scholar 

  • Jenner E (1799) Further observations on the variolae vaccinae. Sampson Low, London

    Google Scholar 

  • Jenner E (1800) A continuation of facts and observations relative to the variolae vaccinae, or cowpox. Sampson Low, London

    Google Scholar 

  • Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE (1969) An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 89:405–421

    CAS  PubMed  Google Scholar 

  • Kaslow DC, Biernaux S (2015) RTS,S: Toward a first landmark on the malaria vaccine technology roadmap. Vaccine 33:7425–7432. https://doi.org/10.1016/j.vaccine.2015.09.061s0264-410x(15)01337-7 [pii]

  • Kim DK, Bridges CB, Harriman KH (2016) Advisory Committee on Immunization Practices AAIWG (2016) Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older—United States. MMWR Morb Mortal Wkly Rep 65:88–90. https://doi.org/10.15585/mmwr.mm6504a5

    Article  PubMed  Google Scholar 

  • Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, Parrott RH (1969) Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 89:422–434

    CAS  PubMed  Google Scholar 

  • Kim JH, Excler JL, Michael NL (2015) Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection. Annu Rev Med 66:423–437. https://doi.org/10.1146/annurev-med-052912-123749

    Article  CAS  PubMed  Google Scholar 

  • Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT (1992) Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 89:12180–12184

    CAS  PubMed  PubMed Central  Google Scholar 

  • Klein NP, Bartlett J, Fireman B, Baxter R (2016) Waning Tdap effectiveness in adolescents. Pediatrics 137:1–9. https://doi.org/10.1542/peds.2015-3326

    Article  Google Scholar 

  • Klein NP, Bartlett J, Fireman B, Rowhani-Rahbar A, Baxter R (2013) Comparative effectiveness of acellular versus whole-cell pertussis vaccines in teenagers. Pediatrics 131:e1716–e1722. https://doi.org/10.1542/peds.2012-3836

    Article  PubMed  Google Scholar 

  • Koepke R et al (2014) Estimating the effectiveness of tetanus-diphtheria-acellular pertussis vaccine (Tdap) for preventing pertussis: evidence of rapidly waning immunity and difference in effectiveness by Tdap brand. J Infect Dis 210:942–953. https://doi.org/10.1093/infdis/jiu322

    Article  CAS  PubMed  Google Scholar 

  • Kost RG, Straus SE (1996) Postherpetic neuralgia–pathogenesis, treatment, and prevention. N Engl J Med 335:32–42. https://doi.org/10.1056/NEJM199607043350107

    Article  CAS  PubMed  Google Scholar 

  • Kramarz P et al (2001) Population-based study of rotavirus vaccination and intussusception. Pediatr Infect Dis J 20:410–416

    CAS  PubMed  Google Scholar 

  • Kreimer AR et al (2015) Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials. Lancet Oncol 16:775–786. https://doi.org/10.1016/S1470-2045(15)00047-9

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lal H et al (2015) Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 372:2087–2096. https://doi.org/10.1056/NEJMoa1501184

    Article  PubMed  Google Scholar 

  • Lee LA et al (2013) The estimated mortality impact of vaccinations forecast to be administered during 2011–2020 in 73 countries supported by the GAVI alliance. Vaccine 31(Suppl 2):B61–B72. https://doi.org/10.1016/j.vaccine.2012.11.035

  • Levin MJ et al (2003) Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis 188:1336–1344. https://doi.org/10.1086/379048 (JID30798 [pii])

  • Lieberman JM et al (2006) The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody. Pediatr Infect Dis J 25:615–622. https://doi.org/10.1097/01.inf.0000220209.35074.0b00006454-200607000-00010 [pii]

  • Liko J, Robison SG, Cieslak PR (2013) Priming with whole-cell versus acellular pertussis vaccine. N Engl J Med 368:581–582. https://doi.org/10.1056/nejmc1212006

  • Lopez AS et al (2006) One dose of varicella vaccine does not prevent school outbreaks: is it time for a second dose? Pediatrics 117:e1070–1077. https://doi.org/10.1542/peds.2005-2085 (117/6/e1070 [pii])

  • Marin M, Guris D, Chaves SS, Schmid S, Seward JF, Advisory Committee on Immunization Practices CfDC, Prevention (2007) Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 56:1–40

    Google Scholar 

  • Marin M, Marlow M, Moore KL, Patel M (2018) Recommendation of the Advisory Committee on Immunization Practices for use of a third dose of mumps virus-containing vaccine in persons at increased risk for mumps during an outbreak. MMWR Morb Mortal Wkly Rep 67:33–38. https://doi.org/10.15585/mmwr.mm6701a7

    Article  PubMed  PubMed Central  Google Scholar 

  • Medical Research Council (1956) Vaccination against whooping-cough; relation between protection in children and results of laboratory tests; a report to the Whooping-cough Immunization Committee of the Medical Research Council and to the medical officers of health for Cardiff, Leeds, Leyton, Manchester, Middlesex, Oxford, Poole, Tottenham, Walthamstow, and Wembley. Br Med J 2:454–462

    Google Scholar 

  • Miller AE (1980) Selective decline in cellular immune response to varicella-zoster in the elderly. Neurology 30:582–587

    CAS  PubMed  Google Scholar 

  • Misegades LK, Winter K, Harriman K, Talarico J, Messonnier NE, Clark TA, Martin SW (2012) Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010. JAMA 308:2126–2132. https://doi.org/10.1001/jama.2012.14939

    Article  Google Scholar 

  • Morrison VA et al (2015) Long-term persistence of zoster vaccine efficacy. Clin Infect Dis 60:900–909. https://doi.org/10.1093/cid/ciu918ciu918 [pii]

  • Morse JL (1913) Whooping-cough: a plea for more efficient public regulations relative to the control of this most serious and fatal disease. JAMA 60:1677–1680

    Google Scholar 

  • Murphy TV et al (2001) Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 344:564–572. https://doi.org/10.1056/NEJM200102223440804

    Article  CAS  PubMed  Google Scholar 

  • Murray NE, Quam MB, Wilder-Smith A (2013) Epidemiology of dengue: past, present and future prospects. Clin Epidemiol 5:299–309. https://doi.org/10.2147/clep.s34440

  • Nair H et al (2010) Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375:1545–1555. https://doi.org/10.1016/S0140-6736(10)60206-1

    Article  PubMed  PubMed Central  Google Scholar 

  • Novartis Vaccines and Diagnostics (2015) BEXSERO® (Meningococcal Group B Vaccine) package insert. Cambridge, MA

    Google Scholar 

  • Oxman MN (1995) Immunization to reduce the frequency and severity of herpes zoster and its complications. Neurology 45:S41–S46

    CAS  PubMed  Google Scholar 

  • Oxman MN et al (2005) A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 352:2271–2284. https://doi.org/10.1056/nejmoa051016 (352/22/2271 [pii])

  • Paavonen J et al (2007) Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369:2161–2170

    CAS  PubMed  Google Scholar 

  • Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J, Group IS (2003) Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants. Pediatr Infect Dis J 22:823–827. https://doi.org/10.1097/01.inf.0000086403.50417.7c

    Article  Google Scholar 

  • Peltola H, Kayhty H, Virtanen M, Makela PH (1984) Prevention of Hemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine. N Engl J Med 310:1561–1566. https://doi.org/10.1056/NEJM198406143102404

    Article  CAS  PubMed  Google Scholar 

  • Plosker GL (2012) A/H5N1 prepandemic influenza vaccine (whole virion, vero cell-derived, inactivated) [Vepacel(R)]. Drugs 72:1543–1557. https://doi.org/10.2165/11209650-000000000-00000

    Article  CAS  PubMed  Google Scholar 

  • Plotkin SA (2014) The pertussis problem Clin Infect Dis 58:830–833. https://doi.org/10.1093/cid/cit934

    Article  PubMed  Google Scholar 

  • Polack FP (2007) Atypical measles and enhanced respiratory syncytial virus disease (ERD) made simple. Pediatr Res 62:111–115. https://doi.org/10.1203/PDR.0b013e3180686ce0

    Article  PubMed  Google Scholar 

  • Prevots DR, Sutter RW, Strebel PM, Weibel RE, Cochi SL (1994) Completeness of reporting for paralytic poliomyelitis, United States, 1980 through 1991. Implications for estimating the risk of vaccine-associated disease. Arch Pediatr Adolesc Med 148:479–485

    CAS  PubMed  Google Scholar 

  • Provost PJ, Hilleman MR (1979) Propagation of human hepatitis A virus in cell culture in vitro. Proc Soc Exp Biol Med 160:213–221

    CAS  PubMed  Google Scholar 

  • Provost PJ, Hughes JV, Miller WJ, Giesa PA, Banker FS, Emini EA (1986) An inactivated hepatitis A viral vaccine of cell culture origin. J Med Virol 19:23–31

    CAS  PubMed  Google Scholar 

  • Purcell RH, D’Hondt E, Bradbury R, Emerson SU, Govindarajan S, Binn L (1992) Inactivated hepatitis A vaccine: active and passive immunoprophylaxis in chimpanzees. Vaccine 10(Suppl 1):S148–S151

    PubMed  Google Scholar 

  • Rauh LW, Schmidt R (1965) Measles immunization with killed virus vaccine. Serum Antibody Titers and Experience with Exposure to Measles Epidemic. Am J Dis Child 109:232–237

    CAS  PubMed  Google Scholar 

  • Rendi-Wagner P, Korinek M, Winkler B, Kundi M, Kollaritsch H, Wiedermann U (2007) Persistence of seroprotection 10 years after primary hepatitis A vaccination in an unselected study population. Vaccine 25:927–931. https://doi.org/10.1016/j.vaccine.2006.08.044

  • Reyes IS, Hsieh DT, Laux LC, Wilfong AA (2011) Alleged cases of vaccine encephalopathy rediagnosed years later as Dravet syndrome. Pediatrics 128:e699–e702. https://doi.org/10.1542/peds.2010-0887

    Article  PubMed  Google Scholar 

  • Richie TL et al (2015) Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines. Vaccine 33:7452–7461. https://doi.org/10.1016/j.vaccine.2015.09.096s0264-410x(15)01386-9 [pii]

  • Roper M, Wassilak S, Tiwari T, Orenstein W (2013) Tetanus toxoid. In: Plotkin SA, Orenstein WA, Offit PA (eds) Vaccines, 6th edn. Saunders/Elsevier, Philadelphia, pp 746–772

    Google Scholar 

  • RTS-S Clinical Trials Partnership (2015) Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386:31–45. https://doi.org/10.1016/s0140-6736(15)60721-8s0140-6736(15)60721-8 [pii]

  • Sabchareon A et al. (2012) Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 380:1559–1567. https://doi.org/10.1016/s0140-6736(12)61428-7 (S0140-6736(12)61428-7 [pii])

  • Safaeian M et al (2013) Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica vaccine trial. Cancer Prev Res (Phila) 6:1242–1250. https://doi.org/10.1158/1940-6207.capr-13-0203

  • Sako W (1947) Studies on pertussis immunization. J Pediatr 30:29–40

    CAS  PubMed  Google Scholar 

  • Sanofi Pasteur (2017) Dengue vaccine registered in 19 countries. http://dengue.info/dengue-vaccine-registered-in-19-countries/. Accessed 12 Feb 2018

  • Santosham M, Reid R, Letson GW, Wolff MC, Siber G (1990) Passive immunization for infection with Haemophilus influenzae type b. Pediatrics 85:662–666

    CAS  PubMed  Google Scholar 

  • Sato H, Sato Y (1990) Protective activities in mice of monoclonal antibodies against pertussis toxin. Infect Immun 58:3369–3374

    CAS  PubMed  PubMed Central  Google Scholar 

  • Schiller JT, Hidesheim A (2000) Developing HPV virus-like particle vaccines to prevent cervical cancer: a progress report. J Clin Virol 19:67–74

    CAS  PubMed  Google Scholar 

  • Schiller JT, Lowy DR (1996) Papillomavirus-like particles and HPV vaccine development. Semin Cancer Biol 7:373–382. https://doi.org/10.1006/scbi.1996.0046

    Article  CAS  PubMed  Google Scholar 

  • Schmader KE et al (2012) Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis 55:1320–1328. https://doi.org/10.1093/cid/cis638cis638 [pii]

  • Schneerson R, Rodrigues LP, Parke JC Jr, Robbins JB (1971) Immunity to disease caused by Hemophilus influenzae type b. II. Specificity and some biologic characteristics of “natural,” infection-acquired, and immunization-induced antibodies to the capsular polysaccharide of Hemophilus influenzae type b. J Immunol 107:1081–1089

    CAS  PubMed  Google Scholar 

  • Schwarz TF, Leo O (2008) Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature. Gynecol Oncol 110:S1–S10. https://doi.org/10.1016/j.ygyno.2008.05.036

    Article  CAS  PubMed  Google Scholar 

  • Seder RA et al (2013) Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 341:1359–1365. https://doi.org/10.1126/science.1241800 [pii]

  • Sheridan SL, Ware RS, Grimwood K, Lambert SB (2012) Number and order of whole cell pertussis vaccines in infancy and disease protection. JAMA 308:454–456. https://doi.org/10.1001/jama.2012.6364

    Article  CAS  PubMed  Google Scholar 

  • Shorvon S, Berg A (2008) Pertussis vaccination and epilepsy—an erratic history, new research and the mismatch between science and social policy. Epilepsia 49:219–225. https://doi.org/10.1111/j.1528-1167.2007.01478.x

    Article  PubMed  Google Scholar 

  • Simmons CP (2015) A candidate dengue vaccine walks a tightrope. N Engl J Med 373:1263–1264. https://doi.org/10.1056/NEJMe1509442

    Article  PubMed  Google Scholar 

  • Slifka MK, Amanna I (2014) How advances in immunology provide insight into improving vaccine efficacy. Vaccine 32:2948–2957. https://doi.org/10.1016/j.vaccine.2014.03.078s0264-410x(14)00459-9 [pii]

  • Stanaway JD et al (2016) The global burden of dengue: an analysis from the Global Burden of Disease Study 2013. Lancet Infect Dis https://doi.org/10.1016/s1473-3099(16)00026-8

  • Stokes J Jr, Neefe JR (1945) The prevention and attenuation of infectious hepatitis by gamma globulin. JAMA 127:144–145

    Google Scholar 

  • Stokley S et al (2014) Human papillomavirus vaccination coverage among adolescents, 2007–2013, and postlicensure vaccine safety monitoring, 2006–2014—United States. MMWR Morb Mortal Wkly Rep 63:620–624

    PubMed  PubMed Central  Google Scholar 

  • Storsaeter J, Hallander HO, Gustafsson L, Olin P (1998) Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 16:1907–1916

    CAS  PubMed  Google Scholar 

  • Strebel PM, Papania MJ, Fiebelkorn AP, Halsey NA (2013) Measles vaccines. In: Plotkin SA, Orenstein WA, Offit PA (eds) vaccines, 6th edn. Saunders/Elsevier, Philadelphia, pp 352–388

    Google Scholar 

  • Tejedor JC et al (2012) Five-year antibody persistence and safety following a booster dose of combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine. Pediatr Infect Dis J 31:1074–1077. https://doi.org/10.1097/INF.0b013e318269433a

    Article  PubMed  Google Scholar 

  • The FUTURE II Study Group (2007) Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356:1915–1927

    Google Scholar 

  • The IMpact RSV Study Group (1998) Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102:531–537

    Google Scholar 

  • Theeten H, Van Herck K, Van Der Meeren O, Crasta P, Van Damme P, Hens N (2015) Long-term antibody persistence after vaccination with a 2-dose Havrix (inactivated hepatitis A vaccine): 20 years of observed data, and long-term model-based predictions. Vaccine 33:5723–5727. https://doi.org/10.1016/j.vaccine.2015.07.008

  • Tiwari T, Wharton M (2013) Diphtheria toxoid. In: Plotkin SA, Orenstein WA, Offit PA (eds) Vaccines, 6th edn. Saunders/Elsevier, Philadelphia, pp 153–166

    Google Scholar 

  • Tseng HF et al (2016) Declining effectiveness of herpes zoster vaccine in adults aged >/=60. Years J Infect Dis. https://doi.org/10.1093/infdis/jiw047 (jiw047 [pii])

  • Van Damme P, Thoelen S, Cramm M, De Groote K, Safary A, Meheus A (1994) Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence. J Med Virol 44:446–451

    PubMed  Google Scholar 

  • Vaughn DW et al (2000) Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity J Infect Dis 181:2–9. https://doi.org/10.1086/315215 (JID990867 [pii])

  • Vazquez M, LaRussa PS, Gershon AA, Steinberg SP, Freudigman K, Shapiro ED (2001) The effectiveness of the varicella vaccine in clinical practice. N Engl J Med 344:955–960. https://doi.org/10.1056/nejm200103293441302 (MJBA-441302 [pii])

  • Villar L et al (2015) Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 372:113–123. https://doi.org/10.1056/NEJMoa1411037

    Article  CAS  PubMed  Google Scholar 

  • von Behring E, Kitasato S (1890) Ueber das zustandekommen der diphtherie-immunitat und der tetanus-immunitat bei thieren (On the realization of immunity in diphtheria and tetanus in animals). Dtsch Med Wochenschr 16:1113–1114

    Google Scholar 

  • Walton LR, Orenstein WA, Pickering LK (2015) Lessons learned from making and implementing vaccine recommendations in the U.S. Vaccine 33(Suppl 4):D78–D82. https://doi.org/10.1016/j.vaccine.2015.09.036

  • Ward JI, Broome CV, Harrison LH, Shinefield H, Black S (1988) Haemophilus influenzae type b vaccines: lessons for the future. Pediatrics 81:886–893

    CAS  PubMed  Google Scholar 

  • Webster DP, Farrar J, Rowland-Jones S (2009) Progress towards a dengue vaccine. Lancet Infect Dis 9:678–687. https://doi.org/10.1016/s1473-3099(09)70254-3 (S1473-3099(09)70254-3 [pii])

  • Werzberger A et al (1992) A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med 327:453–457. https://doi.org/10.1056/NEJM199208133270702

    Article  CAS  PubMed  Google Scholar 

  • Wiedermann G, Kundi M, Ambrosch F, Safary A, D’Hondt E, Delem A (1997) Inactivated hepatitis A vaccine: long-term antibody persistence. Vaccine 15:612–615

    CAS  PubMed  Google Scholar 

  • Williamson ED, Oyston PCF (2013) Plague vaccines. In: Plotkin SA, Orenstein WA, Offit PA (eds) Vaccines, 5th edn. Saunders/Elsevier, Philadelphia, pp 493–503

    Google Scholar 

  • Wilson A, Sharp M, Koropchak CM, Ting SF, Arvin AM (1992) Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation. J Infect Dis 165:119–126

    CAS  PubMed  Google Scholar 

  • Wolters KL, Dehmel H (1942) [Final investigations into tetanus prevention by active immunization] Zeitschrift für hygiene und infektions krankheiten medizinische, mikrobiologie und viralogie 124:326–332

    Google Scholar 

  • World Health Organization (2014) Global control and regional elimination of measles, 2000–2012. Wkly Epidemiol Rec 89:45–52

    Google Scholar 

  • Young MK, Nimmo GR, Cripps AW, Jones MA (2014) Post-exposure passive immunisation for preventing measles. Cochrane Database Syst Rev 4:CD010056 https://doi.org/10.1002/14651858.cd010056.pub2

  • Zhou F et al (2005) Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001. Arch Pediatr Adolesc Med 159:1136–1144. https://doi.org/10.1001/archpedi.159.12.1136 (159/12/1136 [pii])

  • Zingher A (1924) Convalescent whole blood plasma and serum in prophylaxis of measles. JAMA 82:1180–1187

    Google Scholar 

Download references

Acknowledgements

This work was funded in part with federal funds from the National Institute of Allergy and Infectious Diseases R44 AI079898 (to MKS and IJA), R01 AI098723 (to MKS), and Oregon National Primate Research Center grant, P51OD011092 (to MKS). OHSU and Dr. Slifka have a financial interest in Najít Technologies, Inc., a company that may have a commercial interest in the results of this research and technology. This potential individual and institutional conflict of interest have been reviewed and managed by OHSU. Dr. Amanna is an employee of Najít Technologies, Inc. No writing assistance was utilized in the production of this manuscript.

Author information

Authors and Affiliations

  1. Najít Technologies, Inc, Beaverton, OR, 97006, USA

    Ian J. Amanna

  2. Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, 97006, USA

    Mark K. Slifka

Authors
  1. Ian J. Amanna
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark K. Slifka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark K. Slifka .

Editor information

Editors and Affiliations

  1. Dept. of Immunology & Microbiology, The Scripps Research Institute, La Jolla, CA, USA

    Lars Hangartner

  2. Dept. of Immunology & Microbiology, The Scripps Research Institute, La Jolla, CA, USA

    Dennis R. Burton

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Amanna, I.J., Slifka, M.K. (2018). Successful Vaccines. In: Hangartner, L., Burton, D. (eds) Vaccination Strategies Against Highly Variable Pathogens. Current Topics in Microbiology and Immunology, vol 428. Springer, Cham. https://doi.org/10.1007/82_2018_102

Download citation

Publish with us

Policies and ethics

Search

Navigation